A PYMNTS Company

US: Fresenius purchase of NxStage approved

By  |  February 20, 2019

The US Federal Trade Commission (FTC) has given Germany’s Fresenius Medical Care and US home dialysis equipment maker NxStage Medical antitrust approval for their merger, the agency said on Tuesday, February 19.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    To win approval for the US$2 billion deal, the companies agreed to sell NxStage’s bloodline tubing set business, the agency stated. Fresenius and NxStage together dominate the market for the single-use plastic tubes used during dialysis, the agency stated.

    The five FTC commissioners split along party lines in voting on whether to approve the merger. The three Republicans—Joseph Simons, Noah Phillips, and Christine Wilson—voted “yes,” while Democrats Rohit Chopra and Rebecca Slaughter dissented.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.